Published in Bone Marrow Transplant on May 30, 2011
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing. Biomed Res Int (2013) 0.94
Hematopoietic stem and progenitor cell harvesting: technical advances and clinical utility. J Blood Med (2015) 0.91
Applying the Analytic Hierarchy Process in healthcare research: A systematic literature review and evaluation of reporting. BMC Med Inform Decis Mak (2015) 0.90
Plerixafor use for peripheral blood stem cell mobilization in Korea. Blood Res (2013) 0.86
Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica (2013) 0.85
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2014) 0.82
New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis (2012) 0.81
New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients. Biomed Res Int (2014) 0.81
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Blood Transfus (2012) 0.79
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant (2014) 0.77
Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies. Blood Transfus (2014) 0.76
Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean. Bone Marrow Transplant (2015) 0.75
Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature. Blood Transfus (2012) 0.75
Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review. Rev Bras Hematol Hemoter (2015) 0.75
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplant (2016) 0.75
Circulating hematopoietic progenitors and CD34(+) cells predicted successful hematopoietic stem cell harvest in myeloma and lymphoma patients: experiences from a single institution. J Blood Med (2016) 0.75
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transplant (2013) 0.75
Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario. Curr Oncol (2016) 0.75
Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin Wochenschr (2017) 0.75
Consensus methods for medical and health services research. BMJ (1995) 17.94
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia (2007) 3.95
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood (2009) 3.84
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) 2.28
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood (2009) 2.11
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) (2009) 2.06
Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol (2000) 2.05
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant (2008) 1.77
Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant (2009) 1.71
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant (2007) 1.65
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet (1989) 1.57
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol (1994) 1.56
Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol (2000) 1.50
Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol (1995) 1.50
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood (1995) 1.45
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant (2009) 1.31
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia (2007) 1.28
Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program (2009) 1.25
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) 1.24
Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood (1991) 1.23
Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma (2003) 1.19
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2009) 1.18
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant (2006) 1.14
Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant (2009) 1.14
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood (1994) 1.13
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant (2004) 1.09
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood (2003) 1.08
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood (1993) 1.08
Defining a therapeutic dose of peripheral blood stem cells. J Hematother (1992) 1.08
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol (2009) 1.07
Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol (2003) 1.06
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant (2009) 1.05
Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant (2009) 1.04
Mobilization of hematopoietic stem cells. Blood Rev (2000) 1.03
Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.01
Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica (2002) 0.98
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood (2001) 0.98
Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant (1996) 0.97
When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol (1996) 0.97
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res (1998) 0.96
Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci (2009) 0.96
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J (2000) 0.92
The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion (1999) 0.92
How to treat a newly diagnosed young patient with multiple myeloma. Hematology Am Soc Hematol Educ Program (2009) 0.91
Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol (2004) 0.91
Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma (2000) 0.89
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol (2001) 0.89
Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant (2007) 0.89
Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant (2005) 0.88
Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother (1999) 0.88
Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol (2004) 0.87
High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant (2003) 0.86
Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol (1998) 0.86
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol (1995) 0.86
Management strategies for poor peripheral blood stem cell mobilization. Transfus Apher Sci (2008) 0.86
The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant (2003) 0.85
Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion (2009) 0.85
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant (2004) 0.85
The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant (1996) 0.85
Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients. J Clin Apher (2009) 0.84
Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues. Eur J Haematol (2007) 0.84
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica (2006) 0.84
High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant (2002) 0.84
The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion (2004) 0.84
Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells. Transfusion (2005) 0.84
Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion (2008) 0.83
Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant (1998) 0.83
Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica (1998) 0.83
High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol (2008) 0.83
Controversies in the treatment of lymphoma with autologous transplantation. Oncologist (2009) 0.82
Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood (1996) 0.82
Fludarabine combination regimen severely affected peripheral blood stem cell mobilization. Acta Haematol (2004) 0.81
Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex. Transfus Apher Sci (2008) 0.81
Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci (2008) 0.81
Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplant (2004) 0.81
Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplant (2006) 0.81
Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica (2001) 0.80
Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma (2008) 0.80
Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol (2002) 0.80
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia (2006) 0.80
Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant (1997) 0.80
Using at least 5x10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant (1999) 0.80
Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol (1999) 0.80
What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev (2004) 0.80
Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res (2000) 0.79
Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant (2001) 0.79
The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol (1997) 0.78
Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells (1999) 0.78
Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. Jpn J Clin Oncol (2002) 0.78
High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med (1997) 2.73
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol (2004) 2.36
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost (2011) 2.18
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia (2007) 2.09
Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant (2007) 2.03
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun (1995) 1.93
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol (1989) 1.80
Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study. Pain (1993) 1.72
Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J (1999) 1.72
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia (2005) 1.65
Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenoma. Gastroenterology (1992) 1.61
Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice. J Thromb Haemost (2010) 1.57
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet (1989) 1.57
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet (1992) 1.54
A revised model of platelet aggregation. J Clin Invest (2000) 1.54
Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther (2004) 1.53
Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol (1988) 1.53
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia (2006) 1.51
Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst (1990) 1.49
Expression of the M-CSF (CSF-1) gene by human monocytes. Blood (1987) 1.49
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med (1990) 1.47
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood (2001) 1.45
Coagulation and cancer: biological and clinical aspects. J Thromb Haemost (2013) 1.42
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol (1995) 1.42
Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol (1992) 1.42
Cord blood banking. Vox Sang (2008) 1.41
The platelet glycoprotein GPIbbeta intracellular domain participates in von Willebrand factor induced-filopodia formation independently of the Ser 166 phosphorylation site. J Thromb Haemost (2009) 1.41
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40
Walking index for spinal cord injury (WISCI): an international multicenter validity and reliability study. Spinal Cord (2000) 1.40
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1998) 1.40
Further evidence that fibrillar collagen is unable to promote platelet shape change and aggregation in the absence of secondary agonists. J Thromb Haemost (2005) 1.40
Distinctive integrin expression in the newly forming epidermis during wound healing in humans. J Invest Dermatol (1993) 1.39
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Haematologica (1999) 1.39
Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer (1992) 1.39
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia (2007) 1.35
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 1.34
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood (1988) 1.26
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol (1999) 1.26
CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J Virol (1997) 1.26
Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2003) 1.24
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation (2000) 1.24
An endoscopic evaluation of the effects of non-steroidal anti-inflammatory drugs on the gastric mucosa. Gastrointest Endosc (1975) 1.23
Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy (1971) 1.20
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol (2001) 1.20
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant (2007) 1.19
Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. J Clin Virol (1999) 1.19
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest (1987) 1.18
Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood (1999) 1.17
Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy (2008) 1.17
The efficiency of walking of paraplegic patients using a reciprocating gait orthosis. Paraplegia (1995) 1.16
Gene structure, localization and role in oxidative stress of methionine sulfoxide reductase A (MSRA) in the monkey retina. Exp Eye Res (2005) 1.15
Cost of walking and locomotor impairment. J Electromyogr Kinesiol (1999) 1.15
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia (2007) 1.14
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant (2013) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood (1999) 1.14
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther (2004) 1.13
Structure of the gene encoding the human leukocyte adhesion molecule-1 (TQ1, Leu-8) of lymphocytes and neutrophils. J Biol Chem (1990) 1.13
Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol (1996) 1.12
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer (2004) 1.11
A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy (2008) 1.11
Ras oncogene mutation in multiple myeloma. J Exp Med (1989) 1.11
BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood (2001) 1.10
Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. Cytotherapy (2006) 1.09
Glycoprotein (GP) Ib-IX-transfected cells roll on a von Willebrand factor matrix under flow. Importance of the GPib/actin-binding protein (ABP-280) interaction in maintaining adhesion under high shear. J Biol Chem (1999) 1.09
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol (2001) 1.08
Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood (1989) 1.08
Mitochondrial complex I defects in aging. Mol Cell Biochem (1997) 1.08
Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. J Biol Chem (1993) 1.08
Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant (2006) 1.08
Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood (1988) 1.07
T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. J Exp Med (1985) 1.07
CD38: a multi-lineage cell activation molecule with a split personality. Int J Clin Lab Res (1992) 1.06
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia (2004) 1.06
The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem (1999) 1.06
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant (2009) 1.05
Deciding when to intervene: a Markov decision process approach. Int J Med Inform (2000) 1.04
Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol (1996) 1.04
Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood (1997) 1.04